EUVIMEDEUVIMED entdecken
Crossref

FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity

Katrin Panzitt iD, Emilian Jungwirth iD, Lena E Vosko iD, Corina T Madreiter-Sokolowski iD, Tobias Madl iD, Ines Tawfik iD, Hansjörg Habisch iD, Jelena Krstic iD, Andreas Prokesch iD, Robert Karitnig, Robert Sucher, Ceyhun Y Erdogan und 9 weitere

Science Translational Medicine · 13.08.2025 · 17 (811)

DOI: 10.1126/scitranslmed.adn4558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.08.2025. Verfasst von Katrin Panzitt und 20 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit for Translational Nuclear Receptor Research, Division of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austri…. Hauptthemen laut MEDLINE: Obesity, Receptors, Cytoplasmic and Nuclear, Liver, Mitochondria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic pressure shifts signaling pathways of nuclear receptors, including the bile acid receptor FXR, which are sensitive to nutritional inputs. We performed an FXR ChIP-seq–centered multiomic analysis of liver biopsy samples from individuals with or without obesity, who were treated with either placebo or the FXR agonist obeticholic acid, to define metabolic adaptions of FXR signaling pathways. FXR occupied substantially more DNA binding sites in individuals with obesity, and FXR activation by OCA robustly changed the transcriptional output. Integration of ChIP-seq and RNA-seq data showed that mitochondrial function and substrate oxidation were the top metabolic pathways selectively modulated by FXR activation in individuals with obesity. FXR activation restored compromised substrate oxidation by enhancing β-oxidation and oxidative phosphorylation along with antagonizing ROS production. In line with this, the amount of reduced glutathione in patients with obesity normalized after OCA treatment. In summary, FXR signaling profoundly differs in patients with obesity, consisting of changes in DNA binding profiles and transcriptional programs, which enhance energy substrate utilization in this patient cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityReceptors, Cytoplasmic and NuclearLiverMitochondriaMitochondria, LiverHumansOxidation-ReductionMaleSignal TransductionFemaleChenodeoxycholic AcidReactive Oxygen SpeciesAdultMiddle AgedGlutathioneReceptor, Farnesoid X-Activated

Substanzen

Receptors, Cytoplasmic and NuclearChenodeoxycholic AcidReactive Oxygen SpeciesGlutathioneReceptor, Farnesoid X-Activatedobeticholic acid

Autor:innen und Institutionen

  • Research Unit for Translational Nuclear Receptor Research, Division of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.
  • BioTechMed, Graz, Austria.
  • D&F Institute for Pathology, Medical University of Graz, 8010 Graz, Austria.
  • Institute of Biomedical Informatics, Graz University of Technology, 8010 Graz, Austria.
  • Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
  • Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Cell Biology, Histology and Embryology, Medical University of Graz, 8010 Graz, Austria.

ORCID-Profile: Katrin Panzitt, Emilian Jungwirth, Lena E Vosko, Corina T Madreiter-Sokolowski, Tobias Madl, Ines Tawfik, Hansjörg Habisch, Jelena Krstic, Andreas Prokesch, Peter Fickert, Samer Al-Dury, David D Moore, Gerhard G Thallinger, Hanns-Ulrich Marschall, Martin Wagner

Zitieren

APA

Panzitt, K., Jungwirth, E., Vosko, L. E., Madreiter-Sokolowski, C. T., Madl, T., Tawfik, I., Habisch, H., Krstic, J., Prokesch, A., Karitnig, R., Sucher, R., Erdogan, C. Y., Vallim, T. A., Trauner, M., Fickert, P., Al-Dury, S., Molinaro, A., Moore, D. D., Thallinger, G. G., …, & Wagner, M. (2025). FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity. Science Translational Medicine, 17(811). https://doi.org/10.1126/scitranslmed.adn4558

Vancouver

Panzitt K, Jungwirth E, Vosko LE, Madreiter-Sokolowski CT, Madl T, Tawfik I, et al. FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity. Science Translational Medicine. 2025;17(811). doi:10.1126/scitranslmed.adn4558

BibTeX
@article{Panzitt2025,
  author = {Panzitt, Katrin and Jungwirth, Emilian and Vosko, Lena E and Madreiter-Sokolowski, Corina T and Madl, Tobias and Tawfik, Ines and Habisch, Hansjörg and Krstic, Jelena and Prokesch, Andreas and Karitnig, Robert and Sucher, Robert and Erdogan, Ceyhun Y and Vallim, Thomas A and Trauner, Michael and Fickert, Peter and Al-Dury, Samer and Molinaro, Antonio and Moore, David D and Thallinger, Gerhard G and Marschall, Hanns-Ulrich and Wagner, Martin},
  title = {FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {811},
  doi = {10.1126/scitranslmed.adn4558}
}
Kostenlos starten →